> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Cencora Agrees To Buy American Oncology Network In $2.4 Billion Enterprise-Value Deal
- URL: https://www.bullished.co/cencora-agrees-to-buy-american-oncology-network-in-2-4-billion-enterprise-value-deal-72d7f316/
- Published: 2026-10-21T11:56:08.000Z
- Updated: 2026-10-28T19:13:04.000Z
- Description: Cencora would pay about $1.7 billion to lift its stake to 75%, and says fiscal 2026 adjusted EPS will be at least $17.90.
- Author: Matteo Parrino
- Tags: Deals, COR, Industry: Healthcare

Cencora agreed to buy the roughly 96% of American Oncology Network it does not already own, in a deal that values the cancer-practice network at an [enterprise value of $2.4 billion](https://www.sec.gov/Archives/edgar/data/0001140859/000110465926117576/tm2627778d1%5Fex99-1.htm?ref=bullished.co), according to an [8-K](https://www.bullished.co/learn/8-k-items-explained/) filed Wednesday. The same filing raised the company's fiscal 2026 adjusted earnings-per-share outlook to at least $17.90.

## What the deal looks like

The $2.4 billion is made up of $2.3 billion at closing plus contingent value rights of up to $100 million. Those are extra payments Cencora owes only if certain conditions are met.

Cencora holds about 4% of the network, known as AON, and is buying all the equity it does not own. Some AON stockholders may roll over up to 25% of the company. If they keep that full 25%, Cencora expects to pay about $1.7 billion to take its ownership to 75%.

AON is a physician-led group of more than 350 oncology providers across 21 states. Cencora said the purchase adds a presence in twelve more states to its physician-led oncology management business.

Cencora expects the deal to add to its adjusted diluted earnings per share in the second year after closing. AON's board approved it on the unanimous recommendation of a special committee of independent directors.

## The guidance change

Cencora also updated fiscal 2026 guidance, citing strength in its U.S. Healthcare Solutions segment. It now expects adjusted diluted earnings per share of at least $17.90, against a prior range of $17.75 to $17.95.

The company cautioned that its full-year financial closing is not finished, so actual results may change.

CEO Robert P. Mauch said the deal will "expand our physician-led oncology MSO and support of care in communities across the country." AON CEO Todd Schonherz said Cencora, an investor in AON since 2020, "understands that mission." The release says clinical decisions will stay with AON's physicians.

## What to watch

Closing requires regulatory clearances and approval from AON stockholders. Cencora will discuss fiscal 2027 expectations on its fiscal fourth-quarter earnings call on November 4, 2026.

The next dated event is the November 4, 2026 earnings call, where Cencora has said it will lay out fiscal 2027 expectations.

Learn

- [Item 2.02: results of operations →](https://www.bullished.co/learn/8-k-items-explained/#item-202-results-of-operations)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — Cencora, Inc. (COR)](https://www.sec.gov/Archives/edgar/data/0001140859/000110465926117576/tm2627778d1%5F8k.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit tm2627778d1\_ex99-1.htm — Cencora, Inc. 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0001140859/000110465926117576/tm2627778d1%5Fex99-1.htm?ref=bullished.co) — SEC EDGAR
- [Cencora, Inc. (COR) Stock Forecasts](https://finance.yahoo.com/research/reports/MS%5F0P000000ER%5FAnalystReport%5F1792020377000?ref=bullished.co) — Yahoo Finance